IL288034B1 - History of (5,3-dibromo-4-hydroxyphenyl)(6-hydroxy-2-benzofuran-3-yl)methanone and its use in the treatment of gout or hyperuricemia - Google Patents

History of (5,3-dibromo-4-hydroxyphenyl)(6-hydroxy-2-benzofuran-3-yl)methanone and its use in the treatment of gout or hyperuricemia

Info

Publication number
IL288034B1
IL288034B1 IL288034A IL28803421A IL288034B1 IL 288034 B1 IL288034 B1 IL 288034B1 IL 288034 A IL288034 A IL 288034A IL 28803421 A IL28803421 A IL 28803421A IL 288034 B1 IL288034 B1 IL 288034B1
Authority
IL
Israel
Prior art keywords
hyperuricemia
methanone
benzofuran
dibromo
hydroxyphenyl
Prior art date
Application number
IL288034A
Other languages
English (en)
Hebrew (he)
Other versions
IL288034A (en
Original Assignee
Arthrosi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics Inc filed Critical Arthrosi Therapeutics Inc
Publication of IL288034A publication Critical patent/IL288034A/en
Publication of IL288034B1 publication Critical patent/IL288034B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
IL288034A 2019-05-14 2020-05-13 History of (5,3-dibromo-4-hydroxyphenyl)(6-hydroxy-2-benzofuran-3-yl)methanone and its use in the treatment of gout or hyperuricemia IL288034B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847519P 2019-05-14 2019-05-14
PCT/US2020/032725 WO2020232156A1 (en) 2019-05-14 2020-05-13 Compound for treating gout or hyperuricemia

Publications (2)

Publication Number Publication Date
IL288034A IL288034A (en) 2022-01-01
IL288034B1 true IL288034B1 (en) 2026-04-01

Family

ID=73288915

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288034A IL288034B1 (en) 2019-05-14 2020-05-13 History of (5,3-dibromo-4-hydroxyphenyl)(6-hydroxy-2-benzofuran-3-yl)methanone and its use in the treatment of gout or hyperuricemia

Country Status (14)

Country Link
US (1) US20220242841A1 (enExample)
EP (1) EP3968989A4 (enExample)
JP (1) JP7656548B2 (enExample)
KR (1) KR20220016105A (enExample)
CN (1) CN113874014A (enExample)
AU (2) AU2020274165A1 (enExample)
BR (1) BR112021022843A2 (enExample)
CA (1) CA3140412A1 (enExample)
IL (1) IL288034B1 (enExample)
MA (1) MA55973A (enExample)
MX (1) MX2021013980A (enExample)
SG (1) SG11202112562XA (enExample)
TW (1) TW202108561A (enExample)
WO (1) WO2020232156A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2021252630A1 (en) * 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
KR20230050232A (ko) * 2021-10-07 2023-04-14 주식회사 이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
US20250066316A1 (en) * 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) * 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备
US20250242050A1 (en) 2024-01-31 2025-07-31 The Industry & Academic Cooperation In Chungnam National University (Iac) Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2019195118A1 (en) * 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
US12145917B2 (en) * 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Also Published As

Publication number Publication date
AU2020274165A1 (en) 2022-01-06
EP3968989A4 (en) 2022-12-28
SG11202112562XA (en) 2021-12-30
KR20220016105A (ko) 2022-02-08
BR112021022843A2 (pt) 2022-03-03
TW202108561A (zh) 2021-03-01
CN113874014A (zh) 2021-12-31
CA3140412A1 (en) 2020-11-19
IL288034A (en) 2022-01-01
JP2022533958A (ja) 2022-07-27
US20220242841A1 (en) 2022-08-04
WO2020232156A1 (en) 2020-11-19
MA55973A (fr) 2022-03-23
JP7656548B2 (ja) 2025-04-03
MX2021013980A (es) 2022-04-01
AU2026202224A1 (en) 2026-04-09
EP3968989A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
IL288034B1 (en) History of (5,3-dibromo-4-hydroxyphenyl)(6-hydroxy-2-benzofuran-3-yl)methanone and its use in the treatment of gout or hyperuricemia
IL288104B1 (en) Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer
IL307201A (en) Triazine derivatives and their use in cancer treatment.
HUE066282T2 (hu) Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra
IL281999A (en) YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PL3615035T3 (pl) Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii
SI3759083T1 (sl) Derivati 2,4-diaminokinazolina in njihova uporaba v zdravljenju virusnih okužb, raka ali alergij
IL291388A (en) Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment or alleviation of cancer
SG10202002898RA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
ZA201901963B (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
DK3292867T3 (da) Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
IL281495A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
IL273297A (en) Gluconic acid derivatives for use in the treatment and/or prevention of bacterial infections
IL307402A (en) The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer
ZA201904998B (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
PL4346847T3 (pl) Kompleks wielojonowy do stosowania w profilaktyce lub leczeniu zapalenia neurogennego
EP4021906A4 (en) N-(2-AMINOPHENYL)-PROP-2-ENAMIDE DERIVATIVES, AND THEIR USES IN THE TREATMENT OF CANCER
GB2610895C (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB202107297D0 (en) Composition for use in the treatment and/or prevention of mycotoxic disease
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
GB201908110D0 (en) Compositions and methods for use in the treatment of cancer-related fatigue
PL4045022T3 (pl) Kompozycja do zapobiegania taopatiom i ich leczenia